Yorvipath (palopegteriparatide)
Research Synopsis
- Recent studies on Yorvipath (palopegteriparatide) have highlighted its potential as a transformative treatment for hypoparathyroidism, ultimately aiming to address the underlying deficiency in parathyroid hormone (PTH).
- The Phase 3 PaTHway trial demonstrated that 79% of participants treated with TransCon PTH reached normal serum calcium levels, compared to only 5% on placebo, underscoring its efficacy.
- Palopegteriparatide treatment results in improved patient quality of life and significant symptom relief related to hypoparathyroidism.
- Participants in the trials reported better stability in calcium levels, thus moving away from reliance on conventional therapies like active vitamin D and calcium.
- In the 1-year assessment of the PaTHway trial, many participants showed improved renal function, indicating that palopegteriparatide may mitigate the risk of kidney complications associated with chronic hypoparathyroidism.
- The emerging data suggests that palopegteriparatide could effectively maintain normal calcium levels for 24 hours, providing a more consistent therapeutic option compared to existing treatments.
- The long-term results indicate that 81% of participants maintained normal serum calcium levels after 52 weeks of treatment with yet mostly mild side effects.
- Overall, early findings indicate that palopegteriparatide represents a promising shift toward more effective management of hypoparathyroidism and offers better integration into patient care strategies.
- Critical evaluations and ongoing studies are necessary to further ascertain the drug's long-term safety and efficacy.
Yorvipath (palopegteriparatide)
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
London, UK
2 hours ago
1 Received
- - Conventional therapy for hypoparathyroidism, which includes active vitamin D and calcium, doesn't address the underlying issue of parathyroid hormone (PTH) deficiency, making PTH replacement therapy an ideal treatment option.
- - The PaTHway trial tested the efficacy of the investigational drug TransCon PTH over 26 weeks, showing that 79% of participants on TransCon PTH reached normal serum calcium levels and could stop conventional therapy, compared to only 5% on placebo.
- - TransCon PTH significantly improved participants' quality of life and symptoms related to hypoparathyroidism, with a notable percentage achieving independence from traditional treatments and normal urinary calcium levels.
$100 - $150
Hourly Rate
Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.
London, UK
2 hours ago
1 Received
- Conventional treatment for hypoparathyroidism (HypoPT) often involves active vitamin D and calcium, but can lead to unstable calcium levels, kidney issues, and reduced quality of life.
- Replacement therapy with parathyroid hormone (PTH)(1-84) exists but hasn't shown significant benefits, possibly due to its short duration of action.
- A new treatment, palopegteriparatide, offers more stable PTH levels for 24 hours and has shown promising results in maintaining normal calcium levels and improving quality of life in clinical trials.
$100 - $150
Hourly Rate
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
London, UK
2 hours ago
1 Received
- Individuals with chronic hypoparathyroidism on traditional therapy have a higher risk of kidney problems, and new treatments like palopegteriparatide could help improve kidney function while reducing reliance on conventional treatments.
- The PaTHway trial assessed the effects of palopegteriparatide on renal function over 52 weeks, showing promising results such as improved eGFR levels.
- After a year of treatment, many participants achieved normal calcium levels and stopped needing traditional therapies, with significant improvements in kidney function, especially in those with lower baseline eGFR.
$100 - $150
Hourly Rate
[Not Available].
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.
London, UK
2 hours ago
1 Received
- Conventional therapy for hypoparathyroidism helps with hypocalcemia symptoms but doesn't fix low parathyroid hormone (PTH) levels; TransCon PTH (palopegteriparatide) is being studied as a potential long-term treatment.
- A Phase 3 trial involved 82 adults across 21 sites in North America and Europe, with participants receiving TransCon PTH daily during a 156-week open-label period after an initial 26-week placebo-controlled phase.
- Results showed that by week 52, 81% of participants achieved normal serum calcium levels without needing conventional therapy, improved their quality of life, and experienced mostly mild to moderate side effects, indicating the treatment's sustained efficacy and safety.
$100 - $150
Hourly Rate